0001415889-24-004625.txt : 20240221 0001415889-24-004625.hdr.sgml : 20240221 20240221163147 ACCESSION NUMBER: 0001415889-24-004625 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240216 FILED AS OF DATE: 20240221 DATE AS OF CHANGE: 20240221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Yednock Ted CENTRAL INDEX KEY: 0001818525 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39402 FILM NUMBER: 24660149 MAIL ADDRESS: STREET 1: C/O ANNEXON, INC. STREET 2: 180 KIMBALL WAY, SUITE 200 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Annexon, Inc. CENTRAL INDEX KEY: 0001528115 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 275414423 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1400 SIERRA POINT PARKWAY STREET 2: BLDG C, SUITE 200 CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: (650)-822-5500 MAIL ADDRESS: STREET 1: 1400 SIERRA POINT PARKWAY STREET 2: BLDG C, SUITE 200 CITY: BRISBANE STATE: CA ZIP: 94005 4 1 form4-02212024_040217.xml X0508 4 2024-02-16 0001528115 Annexon, Inc. ANNX 0001818525 Yednock Ted C/O ANNEXON, INC 1400 SIERRA POINT PKWY, BLDG C, STE 200 BRISBANE CA 94005 false true false false EVP & CHIEF INNOVATION OFFICER 0 Common Stock 2024-02-16 4 A 0 39000 0 A 75075 D Common Stock 2024-02-20 4 S 0 2604 5.51 D 72471 D Common Stock 21000 I By Spouse Stock Option (Right to Buy) 5.13 2024-02-16 4 A 0 160000 0 A 2034-02-16 Common Stock 160000 160000 D Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 16 of each year, with the first 1/3rd vesting on February 16, 2025. The shares were sold to cover tax withholding obligations in connection with the vesting of RSUs. This transaction was executed in multiple trades in prices ranging from $5.34 to $5.58, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 16, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. /s/ Jennifer Lew, Attorney-in-Fact 2024-02-21